References
- StÜBgen J. P. Neuromuscular disorders in systemic malignancy and its treatment. Muscle Nerve 1995; 18: 636–648
- Rubin D. I., Kimmel D. W., Cascino T. L. Outcome of peroneal neuropathies in patients with systemic malignant disease. Cancer 1998; 83: 1602–1606
- Koehler P. J., Buscher M., Rozeman C. A. M., Leffers P., Twijnstra A. Peroneal nerve neuropathy in cancer patients: a paraneoplastic syndrome?. J. Neurol. 1997; 244: 328–332
- Ryan J. R., Emani A. Vincristine neurotoxicity with residual equinocavus deformity in children with acute leukemia. Cancer 1983; 51: 423–425
- Levitt L. P., Prager D. Mononeuropathy due to vincristine toxicity. Neurology 1975; 25: 894–895
- Legha S. S. Vincristine neurotoxicity. Pathophysiology and management. Med. Toxicol. 1986; 1: 421–427
- Hunger S. P., Link M. P., Donaldson S. S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J. Clin. Oncol. 1994; 12: 2160–2166
- Jones H. R., Gross P. T., Gianturco L., Buchhalter J. Peroneal nerve palsy in children. Muscle Nerve 1987; 10: 664
- Katirji M. B., Wilbourn A. J. Common peroneal mononeuropathy: a clinical and electrophysiologic study of 116 lesions. Neurology 1988; 38: 1723–1728
- Lanskey S. B., Ritter-Sterr C., List M. A., Hart M. J. Psychiatric and psychological support of the child and adolescent with cancer. Principles and Practices of Pediatric Oncology, 2nd edn, P. A. Pizzo, D. G. Poplack. J. B. Lippincott Co, Philadelphia 1993; 1127–1139
- Guiheneuc P., Ginet J., Groleau J. Y., Rojouan J. Early phase of vincristine neuropathy in man. J. Neurol. Sci. 1980; 45: 335–366